COLORADO SPRINGS, Colo., Oct. 6 /PRNewswire-FirstCall/ -- Spectranetics Corporation announces that management will be giving a corporate presentation this afternoon at the Adams Harkness Trends in Peripheral Vascular Disease Conference at the Hyatt Regency hotel in San Francisco.
"We are pleased to be among a select number of innovative medical device firms chosen by Adams Harkness to review the latest trends and advancements in treating peripheral vascular disease," said John Schulte, Spectranetics' president and chief executive officer. "During our company presentation to Adams Harkness institutional clients we will be discussing industry trends, our technology and product advantages, featuring a full line of CLiRpath Catheters including the recently approved 2.5 Turbo."
About Spectranetics
Spectranetics is a medical device company that develops, manufactures and markets single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser system. Its CVX-300(R) excimer laser is the only system approved by the FDA for multiple cardiovascular procedures, including coronary atherectomy, and the removal of problematic pacemaker and defibrillator leads. Nearly all of the company's FDA-approved and investigational applications have received Communautes Europeennes (CE) mark registration for marketing within Europe. In April 2004 Spectranetics obtained 510(k) clearance from the FDA for the laser-based treatment of patients suffering from total occlusions (blockages) in their leg arteries that are not crossable with a guide wire.
Spectranetics, CVX-300, and CLiRpath are registered trademarks of The Spectranetics Corporation.
COMPANY CONTACT: INVESTOR & MEDIA CONTACTS:
Spectranetics Corporation Lippert/Heilshorn & Associates, Inc.
Guy Childs, Chief Financial Officer Bruce Voss or Zachary Bryant
(719) 633-8333 (310) 691-7100
http://www.spectranetics.com/ http://www.lhai.com/
© 2005 PR Newswire
